HOUSTON, June 26 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced changes to the Company's clinical organizational structure, in keeping with its commercialization-focused strategy.
Under the revised clinical structure, medical affairs functions will report to George W. Cole, the Company's Chief Operating Officer; scientific publications and operational management of the Scientific Advisory Board will be led by Richard A.F. Dixon, Ph.D., the Company's Senior Vice President of Research and Chief Scientific Officer; and clinical development will report to a redefined position, Vice President of Clinical Development. This position will temporarily be filled by Bruce D. Given, M.D., the Company's President and Chief Executive Officer, until an ongoing search is completed. As a result of the reorganization, Terrance C. Coyne, M.D., Vice President of Clinical Development and Chief Medical Officer, has left the Company.
"We have been moving toward a commercial structure over the last year, which included the hiring of a Chief Operating Officer, Chief Financial Officer, General Counsel and business unit heads for Europe and Canada," said Dr. Given. "This reorganization continues that effort. We thank Terry for his many contributions and wish him success in his future endeavors." About Encysive Pharmaceuticals Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com/ .
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are decisions by the U.S. Food and Drug Administration and other regulatory authorities regarding whether and when to approve our drug applications for Thelin(TM) (sitaxsentan sodium), as well as more specific risks, trends and uncertainties facing Encysive such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore you should not rely on any such forward-looking statements. Furthermore, Encysive undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion. DATASOURCE: Encysive Pharmaceuticals CONTACT: investors, Ann Tanabe, VP, Investor Relations and Corporate Communications of Encysive Pharmaceuticals, +1-713-796-8822; or Marcy Strickler of The Trout Group, +1-212-477-9007, ext. 27; or media, Dan Budwick of BMC Communications, +1-212-477-9007, ext. 14, both for Encysive Pharmaceuticals Web site: http://www.encysive.com/
|